Literature DB >> 25252046

Japanese pediatric guideline for the treatment and management of bronchial asthma 2012.

Yuhei Hamasaki1, Yoichi Kohno, Motohiro Ebisawa, Naomi Kondo, Sankei Nishima, Toshiyuki Nishimuta, Akihiro Morikawa, Yukoh Aihara, Akira Akasawa, Yuichi Adachi, Hirokazu Arakawa, Toshiichi Ikebe, Kunio Ichikawa, Toshishige Inoue, Tsutomu Iwata, Atsuo Urisu, Yukihiro Ohya, Kenji Okada, Hiroshi Odajima, Toshio Katsunuma, Makoto Kameda, Kazuyuki Kurihara, Tatsuo Sakamoto, Naoki Shimojo, Yutaka Suehiro, Kenichi Tokuyama, Mitsuhiko Nambu, Takao Fujisawa, Takehiko Matsui, Tomoyo Matsubara, Mitsufumi Mayumi, Hiroyuki Mochizuki, Koichi Yamaguchi, Shigemi Yoshihara.   

Abstract

A new version of the Japanese pediatric guideline for the treatment and management of bronchial asthma was published in Japanese at the end of 2011. The guideline sets the pragmatic goal for clinicians treating childhood asthma as maintaining a "well-controlled level" for an extended period in which the child patient can lead a trouble-free daily life, not forgetting the ultimate goal of obtaining remission and/or cure. Important factors in the attainment of the pragmatic goal are: (i) appropriate use of anti-inflammatory drugs; (ii) elimination of environmental risk factors; and (iii) educational and enlightening activities for the patient and caregivers regarding adequate asthma management in daily life. The well-controlled level refers to a symptom-free state in which no transient coughs, wheezing, dyspnea or other symptoms associated with bronchial asthma are present, even for a short period of time. As was the case in the previous versions of the guideline, asthmatic children younger than 2 years of age are defined as infantile asthma patients. Special attention is paid to these patients in the new guideline: they often have rapid exacerbation and easily present chronic asthmatic conditions after the disease is established.
© 2014 Japan Pediatric Society.

Entities:  

Keywords:  asthma; asthma exacerbation; guideline; long-term management

Mesh:

Year:  2014        PMID: 25252046     DOI: 10.1111/ped.12389

Source DB:  PubMed          Journal:  Pediatr Int        ISSN: 1328-8067            Impact factor:   1.524


  9 in total

1.  Efficacy of a leukotriene receptor antagonist for pediatric cedar pollen allergy complicated by asthma.

Authors:  Shigemi Yoshihara; Yutaka Kikuchi; Mari Saitou; Susumu Yanagawa; Noriko Kanno; Hiroshi Igarashi; Hironobu Fukuda; Akiko Iimura; Toshio Abe; Yumi Yamada; Tamotsu Andou; Osamu Arisaka
Journal:  Exp Ther Med       Date:  2017-08-07       Impact factor: 2.447

Review 2.  The use of inhaled corticosteroids in pediatric asthma: update.

Authors:  Elham Hossny; Nelson Rosario; Bee Wah Lee; Meenu Singh; Dalia El-Ghoneimy; Jian Yi Soh; Peter Le Souef
Journal:  World Allergy Organ J       Date:  2016-08-12       Impact factor: 4.084

3.  Oral immunotherapy combined with omalizumab for high-risk cow's milk allergy: a randomized controlled trial.

Authors:  Masaya Takahashi; Kazuhiko Soejima; Shoichiro Taniuchi; Yasuko Hatano; Sohsaku Yamanouchi; Hideki Ishikawa; Makoto Irahara; Youhei Sasaki; Hiroshi Kido; Kazunari Kaneko
Journal:  Sci Rep       Date:  2017-12-12       Impact factor: 4.379

4.  Sensitization to secretoglobin and lipocalins in a group of young children with risk of developing respiratory allergy.

Authors:  Mizuho Nagao; Magnus P Borres; Mayumi Sugimoto; Carl Johan Petersson; Satoshi Nakayama; Yu Kuwabara; Sawako Masuda; Patrik Dykiel; Takao Fujisawa
Journal:  Clin Mol Allergy       Date:  2017-03-03

5.  Multi-season analyses of causative pathogens in children hospitalized with asthma exacerbation.

Authors:  Nozomi Abe; Hiroki Yasudo; Reiji Fukano; Tamaki Nakamura; Seigo Okada; Hiroyuki Wakiguchi; Fumiko Okazaki; Komei Shirabe; Shoichi Toda; Reiko Okamoto; Kazunobu Ouchi; Shouichi Ohga; Shunji Hasegawa
Journal:  Pediatr Allergy Immunol       Date:  2019-08-12       Impact factor: 6.377

6.  LncRNA OIP5‑AS1 aggravates house dust mite‑induced inflammatory responses in human bronchial epithelial cells via the miR‑143‑3p/HMGB1 axis.

Authors:  Xing-Jun Cai; Lin-Hui Huang; Yi-Ke Zhu; Yi-Jiang Huang
Journal:  Mol Med Rep       Date:  2020-09-25       Impact factor: 2.952

7.  Two-weeks-sustained unresponsiveness by oral immunotherapy using microwave heated cow's milk for children with cow's milk allergy.

Authors:  Masaya Takahashi; Shoichiro Taniuchi; Kazuhiko Soejima; Yasuko Hatano; Sohsaku Yamanouchi; Kazuanri Kaneko
Journal:  Allergy Asthma Clin Immunol       Date:  2016-08-26       Impact factor: 3.406

8.  Measurement of Exhaled Nitric Oxide in Children: A Comparison Between NObreath® and NIOX VERO® Analyzers.

Authors:  Yoko Inoue; Sakura Sato; Tetsuharu Manabe; Eishi Makita; Masako Chiyotanda; Kyohei Takahashi; Hitoshi Yamamoto; Noriyuki Yanagida; Motohiro Ebisawa
Journal:  Allergy Asthma Immunol Res       Date:  2018-09       Impact factor: 5.764

9.  Sex Differences in the Prevalence and Severity of Exercise-Induced Bronchoconstriction in Kindergarteners in Japan.

Authors:  Miwa Shinohara; Sigeto Ogawa; Takahiro Nakaya; Ryouji Niino; Masanori Ito; Kaoru Haro; Eiichi Ishii
Journal:  J Gen Fam Med       Date:  2019-08-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.